Journal of Medicinal Chemistry
Article
D. Future hepatitis C virus treatment: interferon-sparing combina-
tions. Liver Int. 2011, 31, 62−67. (c) Cordek, D. G.; Bechtel, J. T.;
Maynard, A. T.; Kazmierski, W. M.; Cameron, C. E. Targeting the
NS5A protein on HCV: an emerging option. Drugs Future 2011, 36,
691−711. (d) Sulkowski, M.; Gardiner, D.; Lawitz, E.; Hinestrosa, F.;
Nelson, D.; Thuluvath, P.; Rodriguez-Torres, M.; Lok, A.; Schwartz,
H.; Reddy, K. R.; Eley, T.; Wind-Rotolo, M.; Huang, J.-P.; Gao, M.;
McPhee, F.; Hindes, R.; Symonds, B.; Pasquinelli, C.; Grasela, D.
Potent viral suppression with all-oral combination of daclatasvir
(22) (a) Chinnaswamy, S.; Murali, A.; Li, P.; Fujisaki, K.; Kao, C. C.
Regulation of de novo-initiated RNA synthesis in hepatitis C virus
RNA-dependent RNA polymerase by intermolecular interactions. J.
Virol. 2010, 84, 5923−5935. (b) Rigat, K.; Wang, Y.; Hudyma, T. W.;
Ding, M.; Zheng, X.; Gentles, R. G.; Beno, B. R.; Gao, M.; Roberts, S.
B. Ligand-induced changes in hepatitis C virus NS5B polymerase
structure. Antiviral Res. 2010, 88, 197−206.
(23) Li, H.; Shi, S. T. Non-nucleoside inhibitors of hepatitis C virus
polymerase: current progress and future challenges. Future Med. Chem.
2010, 2, 121−141.
(NS5A inhibitor) and GS-7977 (NS5B inhibitor),
ribavirin, in
(24) (a) Sofia, M. J.; Furman, P. A.; Symonds, W. T. 2′-F-2′-C-
Methyl Nucleosides and Nucleotides for the Treatment of Hepatitis C
Virus: From Discovery to the Clinic. In Accounts in Drug Discovery:
Case Studies in Medicinal Chemistry; Barrish, J. C., Carter, P. H., Cheng,
P. T. W., Zhaler, R., Eds.; Royal Society of Chemistry: Cambridge,
U.K., 2010; Vol. 4, pp 238−266. (b) Zhou, X. J.; Pietropaolo, K.;
Chen, J.; Khan, S.; Sullivan-Bolyai, J.; Mayers, D. Safety and
pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase
inhibitor of hepatitis C virus, in healthy subjects. Antimicrob. Agents
Chemother. 2011, 55, 76−81. (c) Sofia, M. J.; Bao, D.; Chang, W.; Du,
J.; Nagaratham, D.; Rachakonda, S.; Reddy, P. G.; Ross, B. S.; Wang,
P.; Zhang, H.-R.; Bansal, S.; Espiritu, C.; Keilman, M.; Lam, A. M.;
Steuer, H. M. M.; Niu, C.; Otto, M. J.; Furman, P. A. Discovery of a β-
D-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-
7977) for the treatment of hepatitis C virus. J. Med. Chem. 2010, 53,
7202−7218. (d) McGuigan, C.; Madela, K.; Aljarah, M.; Gilles, A.;
Brancale, A.; Zonta, N.; Chamberlain, S.; Vernachio, J.; Hutchins, J.;
Hall, A.; Ames, B.; Gorovits, E.; Ganguly, B.; Kolykhalov, A.; Wang, J.;
Muhammad, J.; Patti, J. M.; Henson, G. Design, synthesis and
evaluation of a novel double prodrug: INX-08189. A new clinical
candidate for hepatitis C virus. Bioorg. Med. Chem. Lett. 2010, 20,
4850−4854. (e) Kadow, J. F.; Gentles, R.; Ding, M.; Bender, J.;
Bergstrom, C.; Grant-Young, K.; Hewawasam, P.; Hudyma, T.; Martin,
S.; Nickel, A.; Regueiro-Ren, A.; Tu, Y.; Yang, Z.; Yeung, K.-S.; Zheng,
X.; Chen, B.-C.; Chao, S.; Sun, J.-H.; Li, J.; Mathur, A.; Smith, D.; Wu,
D.-R.; Beno, B.; Hanumegowda, U.; Knipe, J.; Parker, D. D.; Zhuo, X.;
Lemm, J.; Liu, M.; Pelosi, L.; Rigat, K.; Voss, S.; Wang, Y.; Wang, Y.-
K.; Colonno, R.; Gao, M.; Roberts, S. B.; Meanwell, N. A. Discovery of
BMS-791325, an Allosteric NS5B Replicase Inhibitor for the
Treatment of Hepatitis C. Presented at the 243rd National Meeting
of the American Chemical Society, San Diego, CA, March 25−29,
2012; MEDI-23. (f) Vendeville, S.; Lin, T.-I.; Hu, L.; Tahn, A.;
MgGowan, D.; Cummings, M. D.; Amssoms, K.; Last, S.; Devogelaere,
B.; Rouan, M.-C.; Vigen, L.; Berke, J. M.; Dehertogh, P.; Fransen, E.;
Cleiren, E.; van der Heim, L.; Fanning, G.; Van Emeien, K.; Nyanguile,
O.; Simmen, K.; Raboisson, P. Discovery of the Clinical Candidate
TMC 647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus
NS5B Polymerase. Presented at the 18th International Symposium on
Hepatitis C Virus and Related Viruses, Seattle, WA, Sept 8−12, 2011;
Abstract P1.33. (g) Rosario, M.; Chauret, N.; George, S.; Kieffer, T. L.;
Koziel, M. J.; Nicolas, O.; Proulx, L. Therapies for Treating Hepatitis
C Virus Infection. Patent WO 2011/094489, August 4, 2011. (h) Li,
H.; Tatlock, J.; Linton, A.; Gonzalez, J.; Jewell, T.; Patel, L.; Ludlum,
S.; Drowns, M.; Rahavendran, S. V.; Skor, H.; Hunter, R.; Shi, S. T.;
Herlihy, K. J.; Parge, H.; Hickey, M.; Yu, X.; Chau, F.; Nonomiya, J.;
Lewis, C. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-
yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5,a]-pyrimidin-2-yl)-
methyl-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent
and orally available hepatitis C virus polymerase inhibitor. J. Med.
Chem. 2009, 52, 1255−1258. (i) Tran, C. V.; Ruebsam, F.; Murphy, D.
E.; Dragovich, P.; Zhou, Y.; Chen, L.; Kuccera, D. 5,6-Dihydro-1H-
pyridin-2-one compounds. Patent 7,939,524, May 10, 2011 (see also
treatment-naive patients with chronic HCV GT1, 2, or 3. J. Hepatol.
2012, 56 (Suppl. 2), S560.
(17) (a) Kolykhalov, A. A.; Mihalik, K.; Feinstone, S. M.; Rice, C. M.
Hepatitis C virus-encoded enzymatic activities and conserved RNA
elements in the 3′-nontranslated region are essential for virus
replication in vivo. J. Virol. 2000, 74, 2046−2051. (b) Chinnaswamy,
S.; Yarbrough, I.; Palaninathan, S.; Kumar, C. T. R.; Vijayaraghavan,
V.; Demeler, B.; Lemon, S. M.; Sacchettini, J. C.; Kao, C. C. A locking
mechanism regulates RNA synthesis and host protein interaction by
the hepatitis C virus polymerase. J. Biol. Chem. 2008, 283, 20535−
20546. (c) Harrus, D.; Ahmed-El-Sayed, N.; Simister, P. C.; Miller, S.;
Triconnet, M.; Hagedorn, C. H.; Mahias, K.; Rey, F. A.; Astier-Gin, T.;
Bressanelli, S. Further insights into the roles of GTP and the C-
terminus of the hepatitis C virus polymerase in the initiation of RNA
synthesis. J. Biol. Chem. 2010, 285, 32906−32918.
(18) Bressanelli, S.; Tomei, L.; Roussel, A.; Incitti, I.; Vitale, R. L.;
Mathieu, M.; De Francesco, R.; Rey, F. A. Crystal structure of the
RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl.
Acad. Sci. U.S.A. 1999, 96, 13034−13039.
(19) For reviews on NS5B inhibitors see, for example, the following:
(a) Beaulieu, P. L. Recent advances in the development of NS5B
polymerase inhibitors for the treatment of hepatitis C virus infection.
Expert Opin. Ther. Pat. 2009, 19, 145−164. (b) Watkins, W. J.; Ray, A.
S.; Chong, L. S. HCV NS5B polymerase inhibitors. Cur. Opin. Drug
Discovery Dev. 2010, 13, 441−465. (c) Sofia, M. J.; Chang, W.;
Furman, P. A.; Mosley, R. T.; Ross, B. S. Nucleoside, nucleotide, and
non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent
RNA-polymerase. J. Med. Chem. 2012, 55, 2532−2531.
(20) (a) Brown, N. A. Progress towards improving antiviral therapy
for hepatitis C virus polymerase inhibitors. Part 1: nucleoside
analogues. Expert Opin. Invest. Drugs 2009, 18, 709−725. (b) Furman,
P. A.; Lam, A. M.; Murakami, E. Nucleoside analog inhibitors of
hepatitis C virus replication: recent advances, challenges and trends.
Future Med. Chem. 2009, 1, 1429−1452. (c) Sofia, M. J. Nucleotide
prodrugs for HCV therapy. Antiviral Chem. Chemother. 2011, 22, 23−
49.
(21) (a) Le Pogam, S.; Jiang, W.-R.; Leveque, V.; Rajyaguru, S.; Ma,
H.; Kang, H.; Jiang, S.; Singer, M.; Ali, S.; Klumpp, K.; Smith, D.;
́
Symons, J.; Cammack, N.; Najera, I. In vitro selected Con1
subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479
show lack of cross-resistance. Virology 2006, 351, 340−348.
(b) McCown, M. F.; Rajyaguru, S.; Le Pogam, S.; Ali, S.; Jiang, W.-
́
R.; Kang, H.; Symons, J.; Cammack, N.; Najera, I. The hepatitis C
virus replicon presents a higher barrier to resistance to nucleoside
analogs than to non-nucleoside polymerase or protease inhibitors.
Antimicrob. Agents Chemother. 2008, 52, 1604−1612. (c) Le Pogam, S.;
Seshaadri, A.; Ewing, A.; Kang, H.; Kosaka, A.; Yan, J.-M.; Berrey, M.;
́
Symonds, B.; DeLaRosa, A.; Cammack, N.; Najera, I. RG1728 alone or
in combination with pegylated interferon-α2a and ribavirin prevents
hepatitis C virus (HCV) replication and selection of resistant variants
in HCV-infected patients. J. Infect. Dis. 2010, 202, 1510−1519.
(d) Gane, E. J.; Roberts, S. K.; Stedman, C. A. M.; Angus, Q. W.;
́
Ritchie, B.; Elston, R.; Ipe, D.; Morcos, P. N.; Baher, L.; Najera, I.;
Chu, T.; Lopatin, U.; Berrey, M. M.; Bradford, W.; Laughlin, M.;
Shulman, N. S.; Smith, P. F. Oral combination therapy with a
nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic
hepatitis C genotype 1 infection (INFORM-1): a randomized, double-
blind, placebo-controlled, dose-escalation trial. Lancet 2010, 376,
1467−1475.
(25) (a) McKercher, G.; Beaulieu, P. L.; Lamarre, D.; LaPlante, S.;
Lefebvre, S.; Pellerin, C.; Thauvette, L.; Kukolj, G. Specific inhibitors
of HCV polymerase identified using a NS5B with lower affinity for
template/primer substrate. Nucleic Acids Res. 2004, 32, 422−431.
(b) Beaulieu, P. L.; Bos, M.; Bousquet, Y.; Fazal, G.; Gauthier, J.;
̈
Gillard, J.; Goulet, S.; LaPlante, S.; Poupart, M.-A.; Lefebvre, S.;
7665
dx.doi.org/10.1021/jm3006788 | J. Med. Chem. 2012, 55, 7650−7666